Medpace Holdings, Inc. (MEDP)
USD 305.11
(0.95%)
USD 305.11
(0.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.09 Billion USD | 13.64% |
| 2022 | 966.1 Million USD | 36.65% |
| 2021 | 707 Million USD | 20.88% |
| 2020 | 584.89 Million USD | 40.33% |
| 2019 | 416.78 Million USD | 10.19% |
| 2018 | 378.23 Million USD | -15.42% |
| 2017 | 447.18 Million USD | 21.39% |
| 2016 | 368.39 Million USD | -35.43% |
| 2015 | 570.56 Million USD | -17.9% |
| 2014 | 694.94 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.2 Billion USD | 3.99% |
| 2024 Q2 | 1.15 Billion USD | 2.86% |
| 2024 Q1 | 1.12 Billion USD | 2.4% |
| 2023 Q1 | 1.04 Billion USD | 8.52% |
| 2023 Q3 | 1.01 Billion USD | -0.01% |
| 2023 Q4 | 1.09 Billion USD | 8.08% |
| 2023 FY | 1.09 Billion USD | 13.64% |
| 2023 Q2 | 1.01 Billion USD | -3.11% |
| 2022 Q1 | 739.33 Million USD | 4.57% |
| 2022 Q4 | 966.1 Million USD | -1.27% |
| 2022 Q2 | 1.03 Billion USD | 39.61% |
| 2022 FY | 966.1 Million USD | 36.65% |
| 2022 Q3 | 978.54 Million USD | -5.2% |
| 2021 Q1 | 592.43 Million USD | 1.29% |
| 2021 FY | 707 Million USD | 20.88% |
| 2021 Q4 | 707 Million USD | 4.12% |
| 2021 Q3 | 679.05 Million USD | 9.91% |
| 2021 Q2 | 617.82 Million USD | 4.29% |
| 2020 Q3 | 504.51 Million USD | 4.22% |
| 2020 FY | 584.89 Million USD | 40.33% |
| 2020 Q4 | 584.89 Million USD | 15.93% |
| 2020 Q2 | 484.06 Million USD | 15.3% |
| 2020 Q1 | 419.83 Million USD | 0.73% |
| 2019 Q3 | 380.32 Million USD | 6.0% |
| 2019 Q1 | 384.62 Million USD | 1.69% |
| 2019 Q4 | 416.78 Million USD | 9.59% |
| 2019 FY | 416.78 Million USD | 10.19% |
| 2019 Q2 | 358.8 Million USD | -6.71% |
| 2018 Q4 | 378.23 Million USD | -2.63% |
| 2018 Q2 | 428.1 Million USD | -7.33% |
| 2018 Q1 | 461.95 Million USD | 3.3% |
| 2018 FY | 378.23 Million USD | -15.42% |
| 2018 Q3 | 388.45 Million USD | -9.26% |
| 2017 Q3 | 398.62 Million USD | 11.88% |
| 2017 Q2 | 356.28 Million USD | 3.24% |
| 2017 Q4 | 447.18 Million USD | 12.18% |
| 2017 FY | 447.18 Million USD | 21.39% |
| 2017 Q1 | 345.11 Million USD | -6.32% |
| 2016 Q1 | 576.13 Million USD | 0.98% |
| 2016 Q4 | 368.39 Million USD | 0.67% |
| 2016 Q3 | 365.94 Million USD | -36.05% |
| 2016 FY | 368.39 Million USD | -35.43% |
| 2016 Q2 | 572.22 Million USD | -0.68% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | 570.56 Million USD | -17.9% |
| 2015 Q4 | 570.56 Million USD | 0.0% |
| 2014 FY | 694.94 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -2629.275% |
| Biodesix, Inc. | 94.51 Million USD | -1061.579% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -32513.819% |
| Castle Biosciences, Inc. | 86.54 Million USD | -1168.607% |
| DarioHealth Corp. | 38.24 Million USD | -2770.645% |
| Exact Sciences Corporation | 3.32 Billion USD | 66.991% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 38.161% |
| Illumina, Inc. | 4.36 Billion USD | 74.854% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -19520.128% |
| iSpecimen Inc. | 6.07 Million USD | -17962.967% |
| Standard BioTools Inc. | 159.86 Million USD | -586.753% |
| 23andMe Holding Co. | 206.64 Million USD | -431.282% |
| NeoGenomics, Inc. | 739.69 Million USD | -48.424% |
| Inotiv, Inc. | 588.04 Million USD | -86.701% |
| Psychemedics Corporation | 6.59 Million USD | -16539.557% |
| Prenetics Global Limited | 44.01 Million USD | -2394.426% |
| Precipio, Inc. | 3.67 Million USD | -29798.638% |
| RadNet, Inc. | 2.07 Billion USD | 47.048% |
| Sotera Health Company | 2.68 Billion USD | 59.136% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -4965.181% |
| Exagen Inc. | 34.25 Million USD | -3105.483% |
| Natera, Inc. | 691.79 Million USD | -58.699% |
| Aspira Women's Health Inc. | 8.62 Million USD | -12626.069% |
| Neogen Corporation | 1.44 Billion USD | 23.759% |
| Myriad Genetics, Inc. | 312.9 Million USD | -250.872% |
| ICON Public Limited Company | 7.74 Billion USD | 85.832% |
| Bionano Genomics, Inc. | 118.24 Million USD | -828.462% |
| CareDx, Inc | 223.28 Million USD | -391.689% |
| Check-Cap Ltd. | 1.33 Million USD | -82447.218% |
| Twist Bioscience Corporation | 152.97 Million USD | -617.703% |
| Guardant Health, Inc. | 1.62 Billion USD | 32.552% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -62926.13% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -685.191% |
| Sera Prognostics, Inc. | 25.28 Million USD | -4242.357% |
| OPKO Health, Inc. | 622.47 Million USD | -76.372% |
| Personalis, Inc. | 95.65 Million USD | -1047.712% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -12405.495% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -4965.181% |
| MDxHealth SA | 121.92 Million USD | -800.461% |
| Prenetics Global Limited | 44.01 Million USD | -2394.426% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -100148.458% |
| Mainz Biomed B.V. | 12.15 Million USD | -8928.749% |
| Trinity Biotech plc | 83.38 Million USD | -1216.653% |
| Neuronetics, Inc. | 81.64 Million USD | -1244.763% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -32513.819% |